Bio-techne CORP Form 4 insider transactions

BIO-TECHNE Director Julie Bushman acquired 1,640 shares of common stock and 3,777 stock options on October 30, 2025, increasing her beneficial ownership.

BIO-TECHNE Director Joseph D. Keegan reported the acquisition of 1,640 shares of common stock and 3,777 stock options, increasing his beneficial ownership.

BIO-TECHNE Director John L. Higgins was granted 1,640 shares of common stock and 3,777 stock options on October 30, 2025.

BIO-TECHNE Director Alpna Seth acquired 1,640 shares of common stock and was granted 3,777 stock options on October 30, 2025.

BIO-TECHNE Director Amy Herr reported the acquisition of 1,640 common shares and 3,777 stock options, alongside existing indirect holdings.

BIO-TECHNE Director Judith V. Klimovsky reported the acquisition of common stock and new stock options, increasing her beneficial ownership.

BIO-TECHNE Director Rupert Vessey acquired 1,640 shares of common stock and 3,777 stock options, increasing his direct beneficial ownership in the company.

BIO-TECHNE Director Robert V. Baumgartner acquired 1,640 shares of common stock and 3,777 stock options on October 30, 2025.

BIO-TECHNE Director Roeland Nusse exercised stock options and subsequently sold an equal number of common shares in a pre-planned transaction.

BIO-TECHNE Director Robert V. Baumgartner exercised stock options and subsequently sold 17,040 shares of common stock.

BIO-TECHNE Corp's CFO, James Hippel, reported a routine acquisition of common stock from RSU vesting and a subsequent disposition of shares for tax withholding purposes.

A BIO-TECHNE Corp. director reported acquisitions of common stock, restricted stock units, and stock options, alongside a disposition for tax purposes.

BIO-TECHNE CEO Kim Kelderman reported recent equity transactions, including the vesting of restricted stock units, a tax-related disposition, and the acquisition of new performance-based and time-based equity awards.

A Bio-Techne Corp. executive reported significant equity transactions, including the acquisition of new stock options and restricted stock units, alongside the exercise of existing awards.

A recent SEC Form 4 filing details Matthew McManus's acquisition and disposition of BIO-TECHNE common stock, alongside significant new equity grants and future vesting schedules.

Bio-Techne's President of Protein Sciences, William Geist, reported significant new equity grants and routine stock transactions.

Bio-Techne Director John L. Higgins exercised 5,040 stock options at $21.84 per share, increasing his direct common stock holdings to 65,236 shares.

Bio-Techne Corporation's CFO, James Hippel, exercised stock options and subsequently sold a portion of the acquired shares to cover tax liabilities.

BIO-TECHNE Corp's CEO, Kim Kelderman, executed a routine transaction involving the exercise of stock options and a subsequent sale of shares for tax purposes.

BIO-TECHNE Corp's CEO, Kim Kelderman, exercised stock options and increased direct beneficial ownership of common stock, while also disposing of shares to cover tax liabilities.

Amy E. Herr, a Director at BIO-TECHNE Corp, reported exercising stock options and subsequently selling a portion of the acquired shares on June 9, 2025.

Director John L. Higgins exercised stock options to acquire 12,000 shares of Bio-Techne Corp common stock at a price of $21.84 on May 1, 2025.

Rupert Vessey, a director at Bio-Techne Corp, filed an amended Form 4 to correct the exercisable and expiration dates of stock options following a four-for-one stock split.

Shane Bohnen, SVP General Counsel of Bio-Techne Corp, reports the disposition of common stock to cover tax obligations and vesting of restricted stock units.

Director Amy E. Herr reports exercising stock options and selling shares of Bio-Techne Corp, along with details of her direct and indirect holdings.

Director Amy E. Herr reports acquisition and disposal of Bio-Techne Corp stock and stock options.

Matthew McManus, President DGS of Bio-Techne Corp, reports the vesting and subsequent disposal of shares to cover tax obligations.

William Geist, President of Protein Sciences at Bio-Techne Corp, reports the vesting of restricted stock units and the disposition of shares to cover tax obligations.

Bio-Techne Corp's President of Diagnostics and Genomics, Matthew McManus, was granted 15,825 performance-based restricted stock units, vesting in 2027 upon achievement of performance goals.

Kim Kelderman, CEO of Bio-Techne Corp, exercised stock options and sold shares on January 27, 2025, according to a recent SEC filing.